Evicenter
MarkdownMedical informationP&T meetings
Inaxaplin (VX-147)

APOL1-mediated kidney disease

Launch
Not announced
Last updated
162 sources

Clinical evidence

VX20-147-008

37 evidence topics · 1 source

Objective
Location and study date
Study design
Eligibility criteria
Treatment
Study outcomes
Rationale for using safety and tolerability assessments as the primary endpoints
Statistical analysis description
Number of participants (Planned and analyzed)
Description of analysis sets
Results
Participant disposition
Baseline characteristics
Demographics pooled across Study 1 and Study 2
CharacteristicPlacebo (N = 44)Inaxaplin total (N = 134)
Male, n (%)“41 (93.2)”View highlighted excerpt for this quote“128 (95.5)”View highlighted excerpt for this quote
Female, n (%)“3 (6.8)”View highlighted excerpt for this quote“6 (4.5)”View highlighted excerpt for this quote
Age (years), mean (±SD)“36.7 (11.3)”View highlighted excerpt for this quote“36.6 (11.6)”View highlighted excerpt for this quote
BMI (kg/m2), mean (±SD)“27.07 (3.14)”View highlighted excerpt for this quote“26.22 (3.30)”View highlighted excerpt for this quote
White, n (%)“30 (68.2)”View highlighted excerpt for this quote“94 (70.1)”View highlighted excerpt for this quote
Black or African American, n (%)“12 (27.3)”View highlighted excerpt for this quote“32 (23.9)”View highlighted excerpt for this quote
Asian, n (%)“0”View highlighted excerpt for this quote“1 (0.7)”View highlighted excerpt for this quote
American Indian or Alaska Native, n (%)“0”View highlighted excerpt for this quote“3 (2.2)”View highlighted excerpt for this quote
Multiracial, n (%)“1 (2.3)”View highlighted excerpt for this quote“4 (3.0)”View highlighted excerpt for this quote
Other race, n (%)“1 (2.3)”View highlighted excerpt for this quote“0”View highlighted excerpt for this quote
Hispanic or Latino, n (%)“10 (22.7)”View highlighted excerpt for this quote“21 (15.7)”View highlighted excerpt for this quote
Not Hispanic or Latino, n (%)“34 (77.3)”View highlighted excerpt for this quote“113 (84.3)”View highlighted excerpt for this quote
Efficacy results
Health-related quality of life and patient-reported outcomes

Not applicable.

Safety results
Adverse events in the completed MAD cohorts of Study 2
n (%)Placebo (N = 9)Inaxaplin 60 mg once daily (N = 9)Inaxaplin 90 mg once daily (N = 9)Inaxaplin 120 mg once daily (N = 9)Inaxaplin total (N = 27)
Participants with any AEs“5 (55.6)”View highlighted excerpt for this quote“6 (66.7)”View highlighted excerpt for this quote“3 (33.3)”View highlighted excerpt for this quote“3 (33.3)”View highlighted excerpt for this quote“12 (44.4)”View highlighted excerpt for this quote
Mild AEs“4 (44.4)”View highlighted excerpt for this quote“6 (66.7)”View highlighted excerpt for this quote“3 (33.3)”View highlighted excerpt for this quote“3 (33.3)”View highlighted excerpt for this quote“12 (44.4)”View highlighted excerpt for this quote
Moderate AEs“1 (11.1)”View highlighted excerpt for this quote“0”View highlighted excerpt for this quote“0”View highlighted excerpt for this quote“0”View highlighted excerpt for this quote“0”View highlighted excerpt for this quote
Participants with SAEs“0”View highlighted excerpt for this quote“0”View highlighted excerpt for this quote“0”View highlighted excerpt for this quote“0”View highlighted excerpt for this quote“0”View highlighted excerpt for this quote
AEs leading to treatment discontinuation“0”View highlighted excerpt for this quote“1 (11.1)”View highlighted excerpt for this quote“0”View highlighted excerpt for this quote“0”View highlighted excerpt for this quote“1 (3.7)”View highlighted excerpt for this quote
Headache“0”View highlighted excerpt for this quote“2 (22.2)”View highlighted excerpt for this quote“1 (11.1)”View highlighted excerpt for this quote“2 (22.2)”View highlighted excerpt for this quote“5 (18.5)”View highlighted excerpt for this quote
Palpitations“1 (11.1)”View highlighted excerpt for this quote“0”View highlighted excerpt for this quote“1 (11.1)”View highlighted excerpt for this quote“0”View highlighted excerpt for this quote“1 (3.7)”View highlighted excerpt for this quote
Abdominal pain“1 (11.1)”View highlighted excerpt for this quote“0”View highlighted excerpt for this quote“0”View highlighted excerpt for this quote“1 (11.1)”View highlighted excerpt for this quote“1 (3.7)”View highlighted excerpt for this quote
Diarrhea“0”View highlighted excerpt for this quote“0”View highlighted excerpt for this quote“1 (11.1)”View highlighted excerpt for this quote“1 (11.1)”View highlighted excerpt for this quote“2 (7.4)”View highlighted excerpt for this quote
Study limitations
Summary: study limitations

VX20-147-008 enrolled healthy adults at one United States site and tested single doses of 90 to 165 mg and multiple doses of 60 to 120 mg once daily, above the 15 mg and 45 mg once daily doses being evaluated in the phase 2/3 trial, with multiple dosing limited to 14 days. Two of its MAD cohorts were stopped early by sponsor decision: 12 participants after an ECG finding attributed to equipment malfunction and 9 participants because of possible COVID-19 exposure, and both cohorts were repeated with new participants. The Study 2 MAD adverse event table therefore excludes these cohorts and has 9 participants in each dose group and 9 receiving pooled placebo, while the pooled adverse event table includes them. Across both phase 1 studies, 128 of 134 participants receiving inaxaplin (95.5%) were male, which the authors attribute to the exclusion of women of childbearing potential. Pharmacokinetic parameter estimates appear only in online supplementary tables, and the trials were designed and funded by Vertex Pharmaceuticals.